MEDI-528, now recognized as enokizumab , represents a groundbreaking medication targeting the IGF-1R , a crucial protein implicated in several skin diseases . Early clinical findings suggest significant promise for the control of significant itchy skin, particularly in individuals who have failed existing remedies. This antibody demonstrates a dist